Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-α therapy

Journal of Endocrinological Investigation

Volumn 25, Issue 11, 2002, Pages 938-946

  Murdolo, Giuseppe ^a   Francisci, D ^a   Forini, F ^a   Baldelli, F ^a   Angeletti, G ^a   Stagni, G ^a   Santeusanio, F ^a   Calcinaro, F ^a   Falorni, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Addison's disease; Endocrine autoimmunity; Interferon ; Islet autoantibodies; Steroid 21 hydroxylase; Thyroid autoimmunity; Type 1 diabetes mellitus

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INSULIN ANTIBODY; IODINE; LEVOTHYROXINE; PANCREAS ISLET CELL ANTIBODY; RADIOACTIVE IODINE; RECOMBINANT ALPHA INTERFERON; STEROID 21 MONOOXYGENASE ANTIBODY; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE; THYROTROPIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ADULT; AGED; ARTICLE; AUTOIMMUNITY; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ENDOCRINE DISEASE; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GRAVES DISEASE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET CELL; PREVALENCE; PROTEIN EXPRESSION; THYROID DISEASE;

EID: 12244267052     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344065     Document Type: Article

References (44)

1. Quesada J.R., Talpaz M., Rios A., Kurzrock R., Gutterman J.U. Clinical toxicity of interferons in cancer patients: A review. J. Clin. Oncol. 1986, 4: 234-243.
2. Fattovich G., Giustina G., Favarato S. et al. A survey of adverse events in 11,421 patients with chronic viral hepatitis treated with interferon. J. Hepatol. 1996, 24: 38-47.
3. Agnello V., Chung R.T., Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 1992, 327: 1490-1495.
4. Johnson R.J., Gretch D.R. Yamabe H. et al. Membrano-proliferative glomerulonephritis associated with hepatitis C virus infection. N. Engl. J. Med. 1993, 328: 465-470.
5. Lunel F., Abuaf N., Franguel L. et al. Liver/kidney microsome antibody type I and hepatitis C virus infection. Hepatology 1992, 16: 630-636.
6. Haddad J., Deny, P., Munz-Gotheil C. et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992, 339: 321-323.
7. Fernandez-Soto L., Gonzalez A., Escobar-Jimenez F. et al. Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy. Arch. Intern. Med. 1998, 158: 1445-1448.
8. Quaranta J.R., Tran A., Régnier D. et al. High prevalence of antibodies to hepatitis C virus (HCV) in patients with anti-thyroid autoantibodies. J. Hepatol. 1993, 18: 136-138.
9. Rönnblom L.E., Alm G.V., Öberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 1991, 115: 178-183.
10. Loviselli A., Oppo A., Velluzzi F. et al. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: Results of a community-based study in north-western Sardinia. J. Endocrinol. Invest 1999, 22: 660-665.
11. Metcalfe R.A., Ball G., Kudesia G., Weetman, A.P. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid 1997, 7: 412-424.
12. Baudin E., Marcellin P., Pouteau M. et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. 1993, 39: 657-661.
13. Custro N., Montalto G., Scafidi V. et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J. Endocrinol. Invest. 1997, 20: 374-380.
14. Di Cesare E., Previti M., Russo F. et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig. Dis. Sci. 1996, 41: 1672-1677.
15. Imagawa A., Itoh N., Hanafusa T. et al. Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis. Diabetologia 1996, 39: 126.
16. Fabris P., Betterle C., Greggio N.A. et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J. Hepatol. 1992, 28: 514-517.
17. Guerci A.P., Guerci B., Levy-Marchal C. et al. Onset of insulin dependent diabetes mellitus after interferon-alpha therapy for hairy cell leukemia. Lancet 1994, 343: 1167-1168.
18. Murakami M., Iriuchijima T., Mori M. Diabetes mellitus and Interferon-α therapy. Ann. Intern. Med. 1995, 123: 318.
19. Falorni A., Örtqvist E., Persson B., Lernmark Å. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J. Immunol. Methods 1995, 186: 89-99.
20. Karlsen A.E., Hagopian W.A., Grubin C.E. et al. Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc. Natl. Acad. Sci. USA 1991, 89: 2115-2119.
21. Grubin C.E., Daniels T., Toivola B. et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994, 37: 344-350.
22. Gianani R., Rabin D.U., Verge C.F. et al. ICA512 autoantibodies radioassay. Diabetes 1995, 44: 1340-1344.
23. Verge C.F., Stenger D., Bonifacio E. et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial islet Autoantibody Workshop. Diabetes 1998, 47: 1857-1866.
24. Falorni A., Grubin C.E., Takei I. et al. Radioimmunoassay detects the frequent occurrence of autoantibodies to the Mr 65,000 isoform of glutamic acid decarboxylase in Japanese insulin-dependent diabetes. Autoimmunity 1994, 19: 113-125.
25. Falorni A., Nikoshkov A., Laureti S. et al. High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J. Clin. Endocrinol. Metab. 1995, 80: 2752-2755.
26. Mariotti S., Caturegli P., Piccolo P., Barbesino G., Pinchera A. Anti-thyroid peroxidase autoantibodies in thyroid disease. J. Clin. Endocrinol. Metab. 1990, 71: 661-669.
27. Carella C., Amato G., Biondi B. et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm. Res. 1995, 44: 110-114.
28. Vanderpump M.P.J., Tunbridge W.M.G., French J.M. et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.) 1995, 43: 55-68.
29. Sanjeevi C.B., Falorni A., Robertson J., Lernmark Å. Glutamic acid decarboxylase (GAD) in insulin-dependent diabetes mellitus. Diab. Nutr. Metab. 1996, 9: 167-182.
30. Gorus F.K., Goubert P., Semakula C. et al. IA-2 autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 1997, 40: 95-99.
31. Preziati D., La Rosa L., Covini G. et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur. J. Endocrinol. 1995, 132: 587-593.
32. Bjoro T., Gaarder P.I., Smeland E.B., Kornstad L. Thyroid antibodies in blood donors: Prevalence and clinical significance. Acta Endocrinol. (Copenh.) 1984, 105: 324-329.
33. Roti E., Gardini E., Minelli R., Bianconi L., Braverman L.E Prevalence of anti-thyroid peroxidase antibodies in serum in the elderly: Comparison with other tests for anti-thyroid antibodies. Clin. Chem. 1992, 38: 88-92.
34. Gambelunghe G., Forini F., Laureti S., Murdolo G. et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin. Endocrinol. 2000, 52: 565-573.
35. Koivisto V.A., Pelkonen R., Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989, 38: 641-647.
36. Sobel D.O., Ahvazi B. α-Interferon inhibits the development of diabetes in NOD mice. Diabetes 1998, 47: 1867-1872.
37. Ito Y., Takeda N., Ishimori M. et al. Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J. Hepatol. 1999, 31: 215-220.
38. Konrad T., Zeuzem S., Vicini P. et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur. J. Clin. Invest. 2000, 30: 111-121.
39. 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J. Clin. Endocrinol. Metab. 1993, 77: 1439-1441.
40. Roti E., Minelli M., Giuberti T. et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am. J. Med. 1996, 172: 482-487.
41. Wesche B., Jaeckel E., Trautwein C. et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon-alpha therapy for chronic hepatitis C. Gut 2001, 48: 378-383.
42. Gregoria G.V., Pensati P., Iorio R. et al. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 1998, 112: 417-476.
43. Morita S., Arima T., Matsuda M. Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases. J. Clin. Endocrinol. Metab. 1995, 80: 1203-1206.
44. Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B. et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin. Endocrinol. 1996, 44: 635-642.